uOttawa medical scientist leading team bolstering Canada's ability to respond to future pandemics, public health emergencies
image:
With $3M in new federal funding over two years, University of Ottawa Faculty of Medicine molecular virologist Dr. Marc-André Langlois and a multidisciplinary team of collaborators will be a vital part of Canada’s ability to respond effectively to infectious disease threats & future pandemics.
view moreCredit: University of Ottawa
With $3M in new federal funding over two years, University of Ottawa Faculty of Medicine molecular virologist Dr. Marc-André Langlois and a multidisciplinary team of collaborators will be a vital part of Canada’s ability to respond effectively to infectious disease threats & future pandemics.
With this investment from the Canadian Institutes of Health Research (CIHR), the national network of experts led by Dr. Langlois will be able to support large-scale scientific research, protect vulnerable communities, and strengthen the country’s ability to face future health emergencies.
It’s part of a nearly $20M funding package to support research platforms that unite researchers from across Canada to bolster the nation’s pandemic readiness and response capabilities. In the wake of the COVID‑19 pandemic, the Canadian government pushed to support infrastructure that could rapidly pivot to deal with emerging health threats.
Central to that mission has been the pioneering work of Dr. Langlois, a world-class scientist based at the uOttawa Faculty of Medicine who took a prominent national leadership role at the helm of the Coronavirus Variants Rapid Response Network (CoVaRR‑Net), backed by funding from the CIHR.
The cutting-edge “Serology and Diagnostics High-Throughput Facility” (SD-HTF) Dr. Langlois created at the uOttawa Faculty of Medicine during the height of the global pandemic was a central player in the national coronavirus response. (In the pandemic’s early days, Dr. Langlois swiftly retooled his lab and focused his research on developing new diagnostic tools including serological assays, new therapeutics and a plant-derived nasal spray vaccine against SARS-CoV-2, the virus that causes COVID-19.)
Detecting & tracking infectious disease threats
Now, moving forward, uOttawa’s High-Throughput Facility infrastructure – situated in a secure restricted-access biocontainment level 2+ (CL2+) lab at uOttawa’s Faculty of Medicine – will be a cornerstone of Canada’s pandemic preparedness plan so the nation can be as ready as possible for any future pandemics and public health emergencies that crop up.
Dr. Langlois says the collaborative team’s overarching goal is to “sustain the operations and readiness of a national research platform that can rapidly detect and track new infectious disease threats while protecting vulnerable people and communities.”
The High-Throughput Facility created by Dr. Langlois is highly unique. It’s the “only academic, infectious-disease-focused high-throughput diagnostic facility in Canada capable of handling population-scale studies,” he says, and it can also support expansive clinical trials such as evaluating vaccines or new antiviral drugs.
“The uOttawa Serology and Diagnostics High-Throughput Facility ensures Canada is prepared to face the next health emergency with real-time evidence to guide public health action, while also supporting homegrown discoveries and technologies that require population-scale testing,” says Dr. Langlois, a full professor in the Faculty’s Department of Biochemistry, Microbiology, and Immunology.
Preparing to face a future health emergency with real-time evidence
How does Dr. Langlois, who holds the Faculty of Medicine Chair of Excellence in Pandemic Viruses and Preparedness Research, define success for this pandemic preparedness research platform?
“Success over the next two years will mean keeping our teams and infrastructure running at full capacity, expanding testing to cover threats like avian influenza and other emerging diseases, and delivering timely infectious-disease data that directly informs Canada’s public health policies and preparedness plans,” he says.
The platform that Dr. Langlois will steer as principal investigator will bring together a network that extends across Canada. Locally, it includes top scientific talent from the University of Ottawa, The Ottawa Hospital and the Bruyère Research Institute.
“Together, this collaborative network allows us to work across disciplines and translate scientific discoveries into coordinated national responses more quickly and effectively,” Dr. Langlois says.
In a government press release, Dr. Paul Hébert, CIHR president and a uOttawa Faculty of Medicine professor, described the initiatives being funded as reflecting "the best of Canadian research."
Global virus network launches multi-country mpox diagnostic evaluation to close global preparedness gaps
Global Virus Network
Tampa, FL, USA – September 25, 2025 – With global attention shifting away from mpox after recent declines in case counts, the Global Virus Network (GVN) is warning against complacency and urges accelerating efforts to strengthen outbreak readiness. Through its Mpox Action Committee and Centers of Excellence, GVN has initiated one of the first coordinated, multi-country evaluations of rapid point-of-care mpox diagnostics, a critical step to prevent resurgence and ensure the world is better prepared for future epidemics.
Despite recent improvements, health experts caution that gaps in surveillance and diagnostics leave communities vulnerable to new flare-ups. In regions where mpox has persisted, such as the Democratic Republic of the Congo (DRC) and surrounding countries, the absence of validated, widely accessible rapid tests continues to undermine timely response.
Globally, the ongoing outbreak of clade IIb mpox, driven by the subclade IIb, has caused more than 100,000 cases in 122 countries, including 115 countries where mpox had not previously been reported.
“Declining numbers should not lull us into a false sense of security,” said Robert C. Gallo, MD, co-founder & international scientific director of the GVN. “When surveillance wanes, resurgence follows. This coordinated study compares mpox diagnostics across multiple countries using a common approach, and it will help set the standard for outbreak preparedness worldwide.” Dr. Gallo is also the James P. Cullison Professor of Medicine, director of the Institute of Translational Virology and Innovation at the University of South Florida, and director of the Microbial Oncology Program at Tampa General Hospital Cancer Institute.
GVN’s coordinated effort spans four countries and includes leading scientists from Emory University (USA), the University of St Andrews (UK), the Institute of Human Virology Nigeria, and the University of Health Sciences Otukpo (Nigeria). Teams are comparing rapid diagnostic kits against gold-standard PCR assays, testing their performance on real clinical samples, and analyzing operational feasibility in resource-limited settings.
“The absence of validated, widely accessible point-of-care diagnostics has created a dangerous blind spot in mpox outbreak response,” added Sten Vermund, MD, PhD, chief medical officer of the GVN and dean of the University of South Florida College of Public Health. “Our Nigeria-Scotland GVN global team is building the evidence base that will guide which tools frontline health workers can rely on the next time mpox, or another virus, threatens public health.”
The study represents a rare, coordinated validation of mpox diagnostics across diverse African sites under both laboratory and field conditions. Findings will be consolidated into a global comparative analysis and policy brief to guide governments, funders, and public health agencies in deploying the most effective rapid tests.
Wilber Sabiiti, PhD, principal research fellow in medicine at the University of St Andrews, spearheads efforts in the DRC and Uganda, validating rapid antigen tests in Kampala metropolitan, Uganda, and South Kivu, DRC, in collaboration with Makerere University and the Catholic University of Bukavu.
“We’re focused not just on how well the kits work, but on whether they’re practical for real-world use in resource-constrained settings,” said Dr. Sabiiti. “That’s the only way to make diagnostics scalable and impactful.”
In Nigeria, Sophia Osawe, MPH, PhD, head of department research operations and senior research manager at the Institute of Human Virology Nigeria, a GVN Center of Excellence, is leveraging her team’s biorepository of mpox samples to compare diagnostic kits under ISO-accredited lab conditions.
“Our goal is to generate the evidence needed to make informed decisions about which tests can be deployed quickly and reliably,” said Dr. Osawe. “The stakes are high as delayed diagnosis means delayed care and unchecked transmission.”
Boghuma Titanji, MD, MSc, DTM&H, PhD, assistant professor of medicine at Emory School of Medicine, a GVN Center of Excellence, uses clinical specimens from the U.S. outbreak to test new rapid assays under (biological safety level) BSL-3 containment conditions to evaluate test sensitivity and operational performance.
“We’re applying rigorous virology to assess these tools, but also considering operational ease,” said Dr. Boghuma. “A test that works in the lab but fails in the field doesn’t help the people who need it most.”
Meanwhile, in Otukpo, Nigeria, Joseph Anejo Okopi, MBA, MSc, PhD, professor of infectious diseases and a former fellow in the GVN Rising Star Mentorship Program, is leading a study at the Federal University of Health Sciences Otukpo to assess how well rapid tests perform across different specimen types and how feasible they are for deployment in rural settings.
“Our research will assess test accuracy and whether community health workers can use them effectively in real-world conditions,” Dr. Okopi said. “This is vital for reaching remote populations often first impacted by outbreaks.”
As each site shares findings with the GVN, the network will develop a comparative manuscript and policy brief to guide the deployment of the most effective mpox POC diagnostics across Africa and globally.
“This is science in action, led by African and global experts working together to outpace the virus,” said Dr. Vermund. “With better diagnostics, we gain the upper hand.”
Media Contact:
Nora Samaranayake
###
About the Global Virus Network
The Global Virus Network (GVN) is a worldwide coalition comprising 80+ Virology Centers of Excellence and Affiliates across 40+ countries, whose mission is to facilitate pandemic preparedness against viral pathogens and diseases that threaten public health globally. GVN advances knowledge of viruses through (i) data-driven research and solutions, (ii) fostering the next generation of virology leaders, and (iii) enhancing global resources for readiness and response to emerging viral threats. GVN provides the essential expertise required to discover and diagnose viruses that threaten public health, understand how such viruses spread illnesses, and facilitate the development of diagnostics, therapies, and treatments to combat them. GVN coordinates and collaborates with local, national, and international scientific institutions and government agencies to provide real-time virus informatics, surveillance, and response resources and strategies. GVN's pandemic preparedness mission is achieved by focusing on Education & Training, Qualitative & Quantitative Research, and Global Health Strategies & Solutions. The GVN is a non-profit 501(c)(3) organization. For more information, please visit www.gvn.org
